Helixmith Attends Pain Meeting at New York Academy of Sciences, Introduces 'Enzensys'
[Asia Economy Reporter Lee Gwan-ju] Helixmith announced on the 4th that it attended the Advances in Pain Meeting hosted by the New York Academy of Sciences (NYAS) and presented on 'Engensis (VM202)'.
The meeting included co-authors such as Professor John Kessler from Northwestern University Feinberg School of Medicine, Helixmith CEO Kim Sun-young, and Vice President William Schmidt. Professor Kessler explained the mechanism of Engensis and presented a comprehensive summary of the results from clinical phases 1, 2, and 3 (3-1) conducted on diabetic peripheral neuropathy (DPN).
Engensis, developed by Helixmith, is a plasmid DNA therapeutic that expresses hepatocyte growth factor (HGF) protein. Rather than simply managing pain, it targets the root cause of neuropathy through angiogenesis and nerve regeneration effects.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 40s Who Kept Girlfriend's Body for a Year After Murder Sentenced to 30 Years in Prison Again on Appeal
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
The U.S. Food and Drug Administration (FDA) previously designated Engensis as a Regenerative Medicine Advanced Therapy (RMAT) in 2018. This is the first pain treatment to be designated as an RMAT in the United States. Currently, the follow-up clinical trial, DPN Phase 3-2, is underway in the U.S.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
